An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients
Status:
Unknown status
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
The aim of current study is to investigate whether the HBsAg clearance rate can be improved
if applying RGT((Response-Guided Therapy) strategy in HBeAg positive CHB(chronic hepatitis B)
patients treated by nucleoside analogue(NUC) achieved HBVDNA<1000copies/ml，and
HBsAg<5000IU/ml; &HBeAg<100PEIU/ml (or470s/co), combined with PEG-IFN a-2a for 24 weeks.